ReachMD

Dr. David A. Kass is the Abraham and Virginia Weiss Professor of Cardiology and professor of biomedical engineering at Johns Hopkins University. He received his baccalaureate degree from Harvard University in 1975, where he graduated summa cum laude in applied physics and engineering, and his medical degree from Yale University in 1980. Following post-graduate training in internal medicine at George Washington University, he joined the cardiology division at Johns Hopkins University in 1983, first as a fellow and later as faculty, where he has remained since.

He is a member of the American Society of Clinical Investigation, Association of University Cardiologists, American Association of Physicians, fellow of the American Heart Association, and associate editor of Circulation Research. He received the inaugural Melvin Marcus Award from the American Heart Association, and was awarded the George E. Brown Memorial Lectureship from the American Heart Association and Janice Pfeffer Lectureship from the International Society of Heart Research in 2004. He has received the Professor's Award for Distinction in Teaching, and the Mentorship Award from Johns Hopkins University, as well as multiple Pfizer Visiting Professor Awards and many additional honorary lectureships. He has published over 250 papers in leading journals, as well as numerous chapters and reviews in leading journals and textbooks, and has a long established funding record from the National Institutes of Heath, American Heart Association, and other agencies. 

Dr. Kass is a world leader in integrative cardiovascular physiology, and has focused his research career on defining the mechanisms of cardiac failure and hypertrophy, and developing novel treatments for these diseases, on the aging heart and vasculature, and on ventricular-arterial interaction. In addition to his primary research efforts and involvement in clinical cardiology, Dr. Kass holds several patents for heart failure diagnostics and novel therapeutics, and is co-founder of Robin Medical, a bio-engineering company developing magnetic resonance imaging based tracking technology, and Cardioxyl, a pharmaceutical company developing nitroxyl as a new treatment for heart failure.